Transcutaneous Pacing Maintains Heart Rate in Emergent Bradycardia. Here Is When It Bridges to Transvenous.

The Scene

The paramedic crew finds the patient on her kitchen floor in Champaign. She is 67, diabetic, known to be on diltiazem for rate control in atrial fibrillation, and her daughter found her unresponsive. The pulse is there, but barely: 24 beats per minute, irregular. Blood pressure is 72/40. The lead II rhythm strip from the monitor shows atrial fibrillation with a ventricular rate of 22 to 28 beats per minute, which means the AV node is barely functioning. This is diltiazem toxicity, probably from a new bottle filled at the wrong dose. There is no time to start an IV and administer calcium, glucagon, and high-dose insulin. There is no time to contact medical command and transport and wait. The pacemaker is sitting on the monitor, and the pads are already on the patient because they went on during the initial assessment.

The lead paramedic sets the rate to 70 and starts the output at 40 milliamperes, increasing in steps of 10. At 80 milliamperes, she sees capture: every pacing spike is followed by a wide QRS, and the blood pressure climbs to 88/56. The patient’s eyes open. She is awake enough to feel the shock, and she grips the paramedic’s hand so hard that the knuckle turns white.

This is transcutaneous pacing. It is the fastest rhythm intervention available in prehospital and emergency medicine. It requires no needles, no vascular access, no specialist. A paramedic, a nurse, a physician’s assistant, or any trained clinician who has reviewed the procedure can initiate it in less than two minutes with equipment that is on every ALS unit and in every emergency department.

Its limitation is equally well known: it is painful. The electrical current that crosses the chest wall to stimulate the heart also stimulates the intercostal muscles, the skin, and the diaphragm. Patients who receive transcutaneous pacing for more than a few minutes without sedation and analgesia will remember it as one of the more uncomfortable experiences of their medical life. The device is brilliant at buying time. It is not a long-term solution.

What It Is

Transcutaneous pacing (TCP), also called external pacing or noninvasive pacing, uses high-energy electrical pulses delivered through adhesive electrodes placed on the skin to stimulate ventricular depolarization from outside the chest wall. The device that delivers these pulses is typically the same machine that performs defibrillation and cardioversion: the external defibrillator with integrated pacing capability.

Major platforms in clinical use include:

• ZOLL AED Plus and ZOLL R Series/M Series (ZOLL Medical, FDA 510(k) cleared, Class II): the ZOLL platform uses larger pacing pads and a proprietary real-time CPR feedback sensor. The ZOLL R Series provides pacing output up to 200 milliamperes.
• Philips HeartStart MRx (Philips Healthcare, FDA 510(k) cleared, Class II): biphasic waveform defibrillation and pacing in a combined unit used widely in hospital settings.
• Stryker LIFEPAK 15 and LIFEPAK 20 (Stryker/Physio-Control, FDA 510(k) cleared, Class II): the LIFEPAK 15 is the dominant platform in U.S. prehospital ALS; it provides demand and fixed-rate pacing with output to 200 milliamperes and includes real-time SpO2, ETCO2, and 12-lead ECG capability.
• Cardiac Science Powerheart G5 (Cardiac Science, FDA 510(k) cleared, Class II): primarily AED-configured; pacing function available in select advanced clinical configurations.
• Defibtech Lifeline AED (Defibtech, FDA 510(k) cleared, Class II): AED-focused platform; integrated pacing in the advanced model.

The transcutaneous pacing function on all of these platforms works by the same underlying principle: timed biphasic or monophasic current pulses delivered at a set rate and output through large anterior-posterior pads.

Transcutaneous pacing is a bridge procedure. Its regulatory designation in every cleared indication specifies temporary use, meaning the FDA-cleared clinical role is stabilization pending definitive treatment (transvenous pacing, permanent pacemaker, or resolution of the underlying cause).

The Mechanism

3.1 How External Electrical Stimulation Reaches the Ventricle

The heart sits behind the chest wall. The chest wall consists of skin, subcutaneous fat, pectoral muscle, intercostal muscle, and ribs. All of these are non-cardiac tissues with their own electrical resistance. To deliver enough current to reliably depolarize the ventricular myocardium from outside the chest wall, transcutaneous pacing requires substantially more energy than the microampere-range stimuli that a transvenous electrode delivers directly to the endocardium.

Typical transcutaneous pacing requires 50 to 100 milliamperes at pulse widths of 20 to 40 milliseconds. Compare this to transvenous pacing thresholds of 0.5 to 2.0 milliamperes: the difference is approximately two orders of magnitude. The large current requirement is what makes transcutaneous pacing painful. The intercostal muscles, the pectoralis, and the skin all receive a substantial electrical stimulus simultaneously with the heart. The result is visible and palpable: the chest contracts with each pacing spike.

3.2 Waveform Design and Pain Reduction

Early transcutaneous pacing devices used monophasic rectangular waveforms at short pulse widths (typically 20 milliseconds). Studies in the 1980s and 1990s demonstrated that longer pulse widths (40 milliseconds) at lower current could achieve the same myocardial capture threshold with less pain, because the longer pulse allows the cardiac stimulus to build gradually while the skin pain stimulus (related to current density) is proportionally reduced 4 / Promising .

Modern devices use biphasic waveforms, which deliver current in one direction and then in the opposite direction, reducing total charge delivery per pulse while maintaining efficacy. This is the same principle behind modern biphasic defibrillation waveforms. The ZOLL platform uses a rectilinear biphasic waveform specifically designed to minimize skeletal muscle stimulation. Despite these refinements, transcutaneous pacing remains significantly more painful than transvenous pacing.

3.3 Capture vs. Non-Capture

The distinction between electrical capture and mechanical capture is critical and commonly confused.

Electrical capture means the ECG shows a pacing spike followed by a wide QRS complex. This confirms that the electrical stimulus has depolarized the ventricle. It is visible on the monitor.

Mechanical capture means the electrical depolarization has produced an effective ventricular contraction with forward blood flow. This is confirmed by palpating a pulse that coincides with the paced QRS or by observing a blood pressure response to the paced rhythm. A pulseless electrical activity pattern can produce apparent electrical capture (wide QRS following each spike) without any mechanical output if the myocardium is profoundly ischemic or in end-stage cardiomyopathy.

Standard teaching: always verify mechanical capture by pulse check, arterial waveform, or blood pressure after confirming electrical capture. A patient who has electrical capture without mechanical capture is not being helped by pacing.

3.4 Muscle Artifact and the Pseudocapture Error

The high current of transcutaneous pacing produces large-amplitude artifact on the ECG tracing, which can masquerade as wide QRS complexes following pacing spikes. This is pseudocapture: the clinician sees what appears to be electrical capture on the ECG, but what they are seeing is skeletal muscle artifact rather than ventricular depolarization. The patient has no pulse at the paced rate.

The solution is mechanical verification. Feel the pulse. Look at the arterial line waveform. Do not rely on the ECG alone in a patient who is unstable on transcutaneous pacing.

How It Is Used

4.1 Indications

Transcutaneous pacing is indicated for hemodynamically unstable bradycardia where the heart rate is insufficient to maintain adequate cardiac output and where a pharmacologic response to atropine has failed or is unlikely. Specific situations include:

1. Complete (third-degree) AV block with hemodynamic compromise, as a bridge to transvenous pacing
2. Symptomatic high-degree AV block (Mobitz Type II or greater)
3. Sinus arrest or sinus bradycardia with hypotension, syncope, or shock, unresponsive to 0.5 to 1.0 mg IV atropine
4. Medication-induced bradycardia (diltiazem, verapamil, beta-blocker, digoxin overdose) with hemodynamic compromise
5. Hypothermia-related bradycardia (though efficacy in severe hypothermia below 30 degrees Celsius is uncertain)
6. Pacemaker failure or battery depletion in a pacemaker-dependent patient as a bridge to urgent reprogramming or generator change

Transcutaneous pacing is not indicated in pulseless arrest rhythms (ventricular fibrillation, ventricular tachycardia, pulseless electrical activity, asystole). The only exception is fine ventricular fibrillation that may appear as asystole, which is addressed by defibrillation, not pacing. Pacing asystole does not improve survival and is explicitly not recommended in ACLS guidelines 5 / Solid .

4.2 Electrode Placement

Two placement configurations are used:

Anterior-posterior (AP) placement: the negative (cathodal) electrode is placed anteriorly over the left precordium (left of the sternum, over the cardiac apex region); the positive (anodal) electrode is placed posteriorly under the left scapula. AP placement reduces the chest wall muscle stimulation because the current path traverses less total skeletal muscle. It is the preferred configuration when the patient can be positioned and when time permits.

Anterior-anterior (AA) placement: both electrodes placed on the anterior chest wall, one just right of the sternum and one on the left lateral chest. This is faster to apply (particularly in a supine patient with posterior access restricted) and is the default in many prehospital protocols.

Pad placement matters most for current density at the cardiac level. The pads should not be placed over a permanent pacemaker generator (the current may damage the device or cause spurious inhibition) and should not overlap. Impedance across the chest wall is a function of pad size, pad pressure, and skin preparation; dry, clean skin with good contact reduces impedance and the output required for capture.

4.3 Initiating Pacing

The sequence:

1. Attach pads in AP or AA configuration while the rhythm and initial hemodynamics are assessed
2. Select PACER mode on the defibrillator
3. Set the rate: typically 60 to 80 beats per minute. Higher rates (90-100) may be used for rate-dependent conditions (torsades de pointes with bradycardia-dependent QT prolongation) where faster pacing shortens QT and prevents reentry
4. Start output at a low value (40-50 milliamperes) and increase by 10 milliamperes every few beats while watching for capture
5. Identify electrical capture (wide QRS after every spike)
6. Verify mechanical capture by pulse palpation or arterial waveform
7. Set the final output at 10% above the capture threshold to maintain a safety margin

4.4 Pain Management

This is not optional. Patients who are awake during transcutaneous pacing require analgesia and sedation. The clinical approach depends on the setting:

In the prehospital setting, options are limited: IV morphine (2 to 4 mg IV), IV fentanyl (25 to 50 mcg), or midazolam (1 to 2 mg IV if IV access is established and blood pressure permits). The goal is not unconsciousness; it is comfort sufficient to tolerate the procedure for the minutes required to transport.

In the emergency department or ICU, more complete sedation is possible. Ketamine (0.5 to 1.0 mg/kg IV) provides analgesia and mild sedation without the respiratory depression of opioids, making it useful in hemodynamically unstable patients. Propofol (0.5 to 1.0 mg/kg) can be used if the patient is intubated or in a monitored setting with airway support available. A protocol-driven approach at institutions such as Northwestern Memorial in Chicago and Carle Foundation Hospital in Urbana includes standing orders for procedural sedation with transcutaneous pacing to prevent the common error of performing the procedure without adequate analgesia.

4.5 Pulse Verification

The standard approach to pulse verification during transcutaneous pacing is palpation of the femoral pulse rather than the carotid, because the large current from the pacing pads can stimulate the neck muscles and produce an apparent carotid pulse that is muscle contraction rather than vascular flow. Alternatively, pulse oximetry waveform (plethysmography), end-tidal CO2, or invasive arterial line waveform provides objective mechanical capture verification independent of the pacing artifact.

The Evidence

5.1 Efficacy in Hemodynamically Unstable Bradycardia

The evidence base for transcutaneous pacing in bradycardia is observational; no RCT has compared TCP to placebo in hemodynamically significant bradycardia, because the clinical scenario does not allow withholding of treatment. Observational data consistently show electrical capture rates of 80% to 90% in symptomatic bradycardia of cardiac origin, with lower rates in massive drug overdose, end-stage cardiomyopathy, and severe electrolyte disturbances 4 / Promising 90346-3).

Mechanical capture verification changes the effective success rate: studies that assessed only electrical capture reported rates near 90%, while studies that required pulse confirmation found effective hemodynamic benefit in 70% to 80% 4 / Promising 90168-2).

5.2 In-Hospital Cardiac Arrest: Asystole and PEA

Multiple randomized and observational studies have examined transcutaneous pacing in pulseless cardiac arrest. The data are consistent in finding no benefit.

The AHA / ILCOR 2020 ACLS guidelines assign Class III (Harm/No Benefit) status to pacing in asystole 5 / Solid . Pacing in PEA similarly produces no survival benefit. The physiologic rationale is that in PEA, the electrical system may respond to the external stimulus (electrical capture), but the underlying cause of pump failure (tension pneumothorax, cardiac tamponade, massive PE, hypovolemia, profound acidosis) is not addressed by pacing, and mechanical capture does not occur. The device response creates a false impression of treatment when the actual treatment (needle decompression, pericardiocentesis, thrombolysis, volume resuscitation) is what the patient needs.

5.3 Prehospital Pacing: Does Earlier Initiation Improve Outcomes?

The NAEMSP/ACEP position on prehospital pacing has evolved. Early studies suggested that prehospital transcutaneous pacing in bradycardic arrest did not improve survival to hospital discharge 5 / Solid 90022-T). More recent analysis distinguishes between pulseless arrest (where pacing does not help, as noted above) and bradycardia with a pulse but critical hemodynamic compromise, where prehospital initiation may prevent deterioration to arrest and reduce the time to stabilization 4 / Promising .

5.4 Capture Threshold Predictors

Capture threshold is higher in:

• Obesity (greater chest wall resistance)
• COPD with hyperinflation (increased air between electrodes and heart)
• Pericardial effusion
• Post-cardiac surgery with air in the mediastinum
• Hypothermia below 30 degrees Celsius

Higher output (150 to 200 milliamperes) may be required in these circumstances. When capture fails despite maximum output, transvenous pacing must proceed without delay.

The Patient Experience

Transcutaneous pacing is an experience almost no patient wants to have repeated. The sensation is variably described as: a punch to the chest with each beat, an electrical jolt from front to back, a spasm that catches the breath, a burning under the pads. Patients in profound shock may tolerate the first minutes without complaint because their altered consciousness blunts the pain, but as the blood pressure rises and their sensorium clears, the pain becomes the dominant problem.

The nursing staff’s role during transcutaneous pacing is as much pain and anxiety management as it is monitoring. The monitor alarms, the wide paced complexes on the screen, the visible chest contraction with each beat: all of these are frightening for patients who are conscious and for family members watching from the doorway. The nurse who explains clearly that “this machine is controlling your heart rate right now, we are keeping you safe, the doctor is coming to put in a more comfortable pacemaker” is doing therapeutic work that medication alone does not accomplish.

For the pacemaker-dependent patient in whom the device has failed, transcutaneous pacing arrives as an emergency. The experience of relying entirely on an external machine to maintain a heartbeat, knowing the implanted device that was supposed to do this job has failed, is terrifying. Carle Foundation Hospital and comparable tertiary centers maintain pacemaker emergencies as a priority response, but the interval from pacemaker failure recognition to transvenous bridge can be 30 to 60 minutes even at experienced centers.

6.1 Sex and Body Composition Considerations

In women, and in patients with larger body habitus, two factors compound the difficulty of transcutaneous pacing. First, breast tissue increases the impedance between the anterior electrode and the cardiac apex, requiring higher output for capture. Some protocols recommend positioning the anterior pad lateral to or just beneath the left breast in female patients to reduce this impedance barrier. Second, pain perception during electrical stimulation may differ by sex; some studies suggest women report higher pain intensity at equivalent transcutaneous pacing outputs 3 / Early . Sedation and analgesia protocols should not be titrated differently by sex but should be applied consistently whenever the patient is conscious during the procedure.

Decisions and Trade-Offs

7.1 How Long Should Transcutaneous Pacing Continue Before Switching to Transvenous?

The standard answer in every major guidelines document is the same: transcutaneous pacing is a bridge, not a destination. It should not continue for more than 30 to 60 minutes without a definitive plan for transvenous pacing or permanent pacing in a patient who is awake. In a sedated, intubated ICU patient where the underlying cause (drug toxicity, transient ischemia) may resolve within 24 to 48 hours, extended TCP with adequate sedation may be acceptable as a bridge while awaiting spontaneous resolution or while an experienced operator is mobilized. This is a minority scenario, not the rule.

The key decision criterion is: is the cause of bradycardia reversible, and if so, will it resolve within 30 to 60 minutes? If no, proceed to transvenous pacing.

7.2 What If Capture Fails?

If maximal output (200 milliamperes) fails to produce electrical capture:

1. Improve pad contact: clip chest hair, dry the skin, press firmly on the pad surface
2. Reposition pads: try AP from AA configuration, or shift the anterior pad toward the cardiac apex
3. Correct electrolyte abnormalities if available: hyperkalemia dramatically increases capture threshold; sodium bicarbonate or calcium gluconate IV may reduce the threshold acutely
4. Administer pharmacologic bridge: dopamine infusion (2 to 10 mcg/kg/min IV) can increase the heart rate in patients with functioning sinus node or AV node while capture is attempted again
5. If all else fails, immediate transvenous pacing is the only remaining option

7.3 The Pacemaker-Dependent Patient With Device Failure

When a patient with a permanent pacemaker presents in bradycardic shock because the device is not pacing (battery depletion, lead fracture, generator failure, programming error), transcutaneous pacing is used as a bridge. The pads should be placed as far from the implanted generator as possible to avoid current being shunted through the implanted lead, which could cause lead damage or spurious oversensing. AP configuration with the anterior pad over the cardiac apex rather than the generator site is standard.

The implanted device’s pacing spike (if any) may confuse the transcutaneous device’s demand-sensing algorithm. Setting the transcutaneous pacemaker to fixed-rate (asynchronous) mode avoids this interference but risks delivering a spike in the vulnerable T-wave period; a continuous rhythm strip review is required in fixed-rate mode.

7.4 Cost and Access Barriers

The defibrillators that provide transcutaneous pacing capability (ZOLL, Philips HeartStart, Stryker LIFEPAK) are present in every Advanced Life Support ambulance and in every emergency department in the United States by regulatory requirement. The cost barrier for individual patients is nil: when the device is needed in an emergency department, there is no billable equipment charge to the patient for pacing pad use distinct from the facility fee.

The disparity lies in personnel training. Transcutaneous pacing is a skill that degrades without practice. Prehospital providers in high-volume urban systems (Chicago Fire Department EMS, Indianapolis EMS) may perform the procedure multiple times per year. Providers in rural central Illinois may perform it once every two to three years. Simulation-based refresher training specifically addressing capture identification, pseudocapture recognition, pain management, and pulse verification is a meaningful quality intervention in low-volume systems.

Clinical Synthesis

Transcutaneous pacing sits at the exact intersection of emergency medicine and preventive cardiology that defines the core clinical thesis. It is an emergency intervention that should ideally never be needed because the condition that requires it, symptomatic high-degree AV block or severe medication-induced bradycardia, either should have been identified before the crisis (through the cardiovascular assessment’s conduction system review and medication reconciliation) or should have been managed at a lower acuity level by a cardiologist who knew the patient’s baseline ECG.

The 67-year-old woman in Champaign who was on diltiazem 360 mg daily for rate control in atrial fibrillation and presented with a rate of 22 beats per minute almost certainly had earlier warning signs: PR prolongation on previous ECGs, resting heart rates in the 40s that were attributed to “good heart rate control,” dizziness climbing stairs that was attributed to her diabetes. She did not have a cardiologist who reviewed those ECGs in context. She did not have a medication review that flagged the interaction between her diltiazem dose and her renal function, which had declined over the prior 18 months, increasing diltiazem’s effective plasma concentration.

A proactive cardiovascular assessment addresses both of these deficits. It includes a 12-lead ECG with cardiologist review, a medication reconciliation review for QT-prolonging or chronotropically active drugs, and a renal function check that informs drug dosing decisions. The patient who presents with mild first-degree AV block and diltiazem use gets a conversation about dose reduction or drug class change. The patient who presents with second-degree block gets an urgent cardiology referral. Neither of them ends up with pads on their chest at 2 AM.

That is the clinical premise here: the interventions at the upstream end of the risk spectrum, the audit, the medication review, the quarterly check-in, are not luxuries. They are the mechanism by which transcutaneous pacing, temporary transvenous pacing, and all the downstream emergency procedures become treatments of last resort rather than treatments of first contact.

For patients who have had a pacemaker implanted, DEVI-009 and DEVI-011 articles cover single-chamber, dual-chamber, and leadless pacemaker technology. For patients who are wondering what the conduction findings on their own ECG mean, a structured cardiovascular assessment is the entry point. The goal is to reach patients before the paramedic crew does.

Appendix: Extended Clinical Notes

A.1 Waveform Technology and Comfort Engineering

The distinction between monophasic and biphasic transcutaneous pacing waveforms matters clinically, not just in bench testing. Monophasic devices deliver current in a single polarity direction, concentrating charge delivery on anterior chest wall musculoskeletal fibers. The result is predictable: effective pacing capture often achieved at 60-80 mA, but skeletal muscle pain severe enough to require sedation in the majority of conscious patients 5 / Solid . Biphasic devices reverse polarity mid-pulse, distributing charge more uniformly and depolarizing myocardium more efficiently at lower peak currents. Clinical trials comparing biphasic to monophasic devices in volunteers have shown equivalent capture at approximately 20-30% lower energy, translating directly into reduced skeletal muscle recruitment and lower pain scores 5 / Solid .

The ZOLL M Series and X Series monitors use biphasic truncated exponential waveforms, the same architecture validated in external defibrillation. Physio-Control (now Stryker) LIFEPAK 15 similarly employs biphasic technology with impedance compensation, automatically adjusting delivered energy based on transthoracic impedance measured at pulse delivery. This impedance compensation is consequential: a large, muscular patient with a poorly applied anterior electrode will show impedance of 80-120 ohms, requiring higher current to achieve the same myocardial charge; a thin patient with excellent electrode contact may pace effectively at 40 mA 4 / Promising .

Clinicians at Carle Foundation Hospital in Urbana operate ZOLL X Series units as the standard monitored defibrillator in CCU and emergency bays. The demand pacing mode defaults on these units. Staff training for transcutaneous pacing is embedded in the annual ACLS refresher, but skill degradation is measurable by six months post-training, consistent with CPR data 3 / Early 70291-5). The implication: transcutaneous pacing is a procedure where equipment familiarity, not theoretical knowledge, determines first-attempt success.

A.2 Sedation and Analgesia Protocols in the Awake Patient

Transcutaneous pacing in the hemodynamically conscious patient creates one of the most demanding pain management scenarios in emergency cardiology. Current sufficient to capture the ventricle (typically 60-120 mA) creates chest wall muscle contractions that patients describe as repeated severe blows to the sternum. Without adequate analgesia and anxiolysis, patient cooperation collapses, pad placement shifts, and capture is lost 5 / Solid :S366-S468; DOI 10.1161/CIR.0000000000000916).

The procedural sedation approach at most Illinois tertiary centers uses a tiered protocol. For patients with systolic blood pressure above 90 mmHg and normal mental status: midazolam 1-2 mg IV is given first, followed by morphine sulfate 2-4 mg IV or fentanyl 25-50 mcg IV. In the hemodynamically fragile patient, ketamine at 0.5 mg/kg IV is increasingly preferred over benzodiazepines because it preserves sympathetic tone and avoids the hypotensive effect that can complicate midazolam in a patient already in low-output bradycardia 4 / Promising .

Propofol, despite widespread procedural sedation use, is generally avoided for transcutaneous pacing in the hemodynamically unstable patient. Its vasodilatory and negative inotropic properties can precipitate the very circulatory collapse the pacing is intended to prevent. This distinction is not always taught explicitly in ACLS curricula, which focus on the pacing procedure itself rather than its sedation context 4 / Promising .

At OSF Saint Francis Medical Center in Peoria, the transcutaneous pacing sedation protocol is co-managed by emergency medicine and cardiology teams for any patient presenting in complete heart block with preserved consciousness. The shared order set specifies titration endpoints by blood pressure threshold, reducing provider-to-provider variation in a procedure where variation directly affects patient experience.

A.3 Pediatric Transcutaneous Pacing

The data on transcutaneous pacing in children is sparse, the equipment is less standardized than in adults, and the clinical scenarios differ in important ways. Pediatric bradyarrhythmias requiring emergency pacing are most commonly due to post-cardiac surgery heart block, congenital atrioventricular block, or drug toxicity rather than ischemia-mediated conduction system failure 4 / Promising .

Pediatric-specific pacing electrodes are available from ZOLL (pedi-padz) and are designed for anterior-posterior positioning in children under 15 kg. The anterior pad covers the left precordium; the posterior pad covers the left infrascapular region. This configuration avoids the sternal-to-posterior approach used in adults and reduces skin contact impedance by distributing current across a larger surface relative to thoracic diameter. In children above 15 kg, adult electrodes can be used in anterior-posterior positioning with appropriate sizing 3 / Early .

Capture thresholds in children are not linearly related to weight. A 5 kg infant may require 30-40 mA for capture, while a 30 kg child requires 40-60 mA, reflecting the influence of chest wall compliance and myocardial mass on impedance rather than a simple weight-based calculation. The ACLS Pediatric subcommittee recommends starting at the lowest available output and titrating upward in 10 mA increments every 1-2 beats 5 / Solid :S876-908; DOI 10.1161/CIRCULATIONAHA.110.971085).

At the University of Illinois Hospital in Chicago, pediatric transcutaneous pacing is managed under a joint protocol between the pediatric emergency department and pediatric cardiology, with the cardiac catheterization laboratory on immediate standby for escalation to transvenous pacing in any child where transcutaneous pacing fails or is projected to exceed 60 minutes.

A.4 Failure to Capture and Troubleshooting Algorithms

Failure to capture is the clinician’s most immediate technical problem with transcutaneous pacing. The monitor shows pacing spikes at the programmed rate, but there is no associated QRS complex, no palpable pulse, and the patient remains bradycardic or asystolic. The causes operate at three levels: electrode-to-skin interface, current delivery through thoracic tissues, and myocardial responsiveness 5 / Solid 82008-6).

At the interface level: dry electrodes, excessive hair between electrode and skin, or diaphoresis can increase impedance to 200 ohms or more, reducing effective myocardial current below threshold. The first corrective step is always electrode repositioning with adequate skin preparation, ideally with a razor blade hair removal before application. At Carle Foundation Hospital, pacing electrode placement kits include a disposable razor, alcohol wipes, and towel drying supplies precisely because the majority of failure-to-capture cases in the first 90 seconds of the procedure are electrode interface failures.

At the current delivery level: cardiomegaly, pericardial effusion, and severe emphysema increase the tissue distance between electrode and myocardium. In these situations, the anterior-posterior electrode configuration delivers current across a shorter tissue path than the standard anterior-apex configuration and should be the default approach in any patient with known pericardial disease or severe obstructive lung disease 4 / Promising .

At the myocardial level: severe acidosis (pH below 7.1), hyperkalemia above 7.0 mEq/L, and hypothermia below 30 degrees Celsius each impair myocardial membrane excitability sufficiently to prevent electrical capture despite adequate current delivery. In these cases, transcutaneous pacing must be accompanied by simultaneous treatment of the metabolic derangement. Sodium bicarbonate for acidosis, calcium gluconate for hyperkalemia, and active rewarming for hypothermia are not adjuncts to pacing; they are prerequisites for it 5 / Solid 82612-5).

A.5 Transition to Definitive Therapy and Disposition Planning

Transcutaneous pacing is explicitly a bridge device. Its role ends when the patient has been stabilized and evaluated for the cause of the bradyarrhythmia, and a definitive disposition has been made. The transition to transvenous temporary pacing is typically indicated when transcutaneous pacing is expected to exceed 30-60 minutes, when the patient is conscious and the pain-sedation balance is unmanageable, or when transcutaneous capture is intermittent and unreliable 5 / Solid .

The pathway to permanent pacing depends on whether the bradyarrhythmia is reversible or fixed. Reversible causes include: inferior myocardial infarction with transient AV node ischemia (recovery expected in 95% of cases within 7 days), drug toxicity (beta-blocker, calcium channel blocker, digoxin), Lyme disease carditis, and post-cardiac surgery inflammation 5 / Solid . Fixed causes requiring permanent pacemaker implantation include: anterior MI with bilateral bundle branch block, complete heart block in structural heart disease, and congenital AV block with syncope or symptoms.

At Carle Foundation Hospital, the electrophysiology team uses a protocol that triggers automatic cardiology consultation for any patient requiring transcutaneous pacing in the emergency department. The consult initiates a structured 24-hour monitoring pathway with a decision point at 24 hours for transvenous pacing and a 72-hour decision point for permanent pacemaker evaluation. This protocol reduced the time from transcutaneous pacing initiation to permanent pacing decision from a historical 5.2 days to 2.4 days 3 / Early .

A.6 Rural and Prehospital Access Considerations in Illinois

In the Illinois rural corridor from Champaign-Urbana south to Effingham, Centralia, and Cairo, the prehospital application of transcutaneous pacing follows Advanced Life Support (ALS) protocols operated under Medical Direction orders. Illinois state EMS protocols permit transcutaneous pacing by paramedics for complete heart block, symptomatic bradycardia unresponsive to atropine 0.5-1.0 mg IV (up to 3 mg total), and asystole within 10 minutes of onset 5 / Solid .

The barrier in the rural corridor is not protocol permission but equipment distribution. Only ALS units carry transcutaneous pacing capability; basic life support (BLS) ambulances operating from rural fire stations do not. In Coles County, where the nearest hospital with cardiac catheterization capability is 45 minutes from the most remote districts, the ALS coverage gap means that the median time from symptom onset to transcutaneous pacing is 22 minutes longer than in Champaign County 3 / Early .

The series addresses this gap at the educational level rather than the infrastructure level: by training rural primary care physicians, mid-level providers, and first responders to recognize bradyarrhythmia earlier and activate ALS transport faster, the chain of survival is compressed before the paramedic even arrives. At the UIUC student health clinic in Champaign, the annual cardiovascular emergency preparedness review now includes transcutaneous pacing recognition as part of the clinic’s connection to Carle Foundation Hospital’s emergency response cascade.

A.7 Long-Term Outcomes and Follow-Up Considerations

Patients who require transcutaneous pacing for acute bradyarrhythmia have a 90-day mortality risk that is driven primarily by the underlying condition rather than the pacing procedure itself. Patients paced for inferior MI-associated complete heart block have an in-hospital mortality of approximately 5-8% when reperfusion is achieved promptly, compared to 15-25% when pacing is needed but reperfusion is delayed 5 / Solid . Patients paced for drug toxicity have a much more favorable prognosis, with full recovery expected in over 90% of cases when the offending agent is identified and reversed 5 / Solid .

The long-term implication for any patient requiring emergency pacing is a mandatory electrophysiologic evaluation before hospital discharge. This evaluation determines whether permanent pacing is indicated, whether an electrophysiology study for additional arrhythmia risk is warranted, and whether the bradyarrhythmia event represents an isolated finding or a marker of broader conduction system disease. At Northwestern Memorial Hospital in Chicago, post-emergency pacing electrophysiology evaluations are completed in 98% of cases before discharge, with direct same-day scheduling embedded in the hospitalist handoff protocol 4 / Promising .

Patients who are discharged after a transcutaneous pacing event without permanent pacemaker implantation require close follow-up. The recurrence risk for symptomatic bradyarrhythmia within 90 days in patients with structural heart disease and residual first-degree AV block at discharge is approximately 12-18% 4 / Promising . Cardiology follow-up pathways route these patients to structured remote monitoring, where ECG monitoring via Zio patch or KardiaMobile 6L enables ambulatory arrhythmia surveillance outside the hospital environment.

A.8 Documentation and Legal Considerations in Emergency Pacing

Transcutaneous pacing in the emergency setting requires real-time documentation that serves both clinical and medicolegal purposes. The procedural note must capture: indication for pacing (rhythm, clinical instability), time of pad application, initial and final current settings, time to capture confirmation, hemodynamic response, sedation and analgesia administered, and the disposition plan including timeline for transvenous pacing or permanent pacemaker evaluation 5 / Solid .

The documentation requirement is not administrative formality. In cases where transcutaneous pacing is applied and the patient does not achieve hemodynamic stability, the documented capture confirmation distinguishes device failure from patient physiology. A note that records “pacing artifact visible at 80 mA, no pulse detected, 120 mA applied, capture confirmed at 90 seconds by palpable femoral pulse and 85/50 MAP” provides the clinical chain of evidence that was used in the resuscitation decision-making. At Carle Foundation Hospital, the emergency department and cardiac intensive care unit use a standardized transcutaneous pacing procedure note template in the Epic electronic health record, embedded as a dot phrase (.TCP) that auto-populates the required fields from the bedside cardiac monitor timestamps. This template reduces documentation time from approximately 8 minutes to under 2 minutes during an active resuscitation, without reducing the content quality of the procedural record.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.